KRAS (G12C) Inhibitor-12

Across CCLE and GDSC cell-line panels, response to KRAS (G12C) Inhibitor-12 is significantly associated with the mutation status of multiple genes, with BLOOD_Leukemia cell lines showing a particularly strong set of associations.

The most reproducible KRAS (G12C) Inhibitor-12 response-associated genes across cancer lineages are PRDM15, HYDIN, and ZFHX3, each associated with drug response in up to 4 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The box plot shows the strongest observed association, KRAS (G12C) Inhibitor-12 response grouped by PRDM15 status in BLOOD_Leukemia.

Mutation status biomarkers of KRAS (G12C) Inhibitor-12 response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Leukemia	PRDM15 →	+2.321	+0.290	.024	.042	3	4
BLOOD_Leukemia	HYDIN →	+2.169	+0.311	.046	.036	3	4
BREAST	ZFHX3 →	+2.649	+0.453	.046	.045	3	3
UPPER_AERODIGESTIVE_TRACT	SYNE1 →	+2.078	+0.385	.029	.046	3	3
UPPER_AERODIGESTIVE_TRACT	LRP1B →	+3.078	+0.517	.007	.008	3	3
BLOOD_Leukemia	MXRA5 →	+3.000	+0.264	.023	.035	3	3

Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

KRAS (G12C) Inhibitor-12 response by PRDM15 status — BLOOD_Leukemia

Explore this box plot interactively →